NCT02094872 - Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions

Recurrent MelanomaStage IIIA MelanomaStage IIIB MelanomaStage IIIC MelanomaStage IV Melanoma

Interventions

OTHER

cytology specimen collection procedure

Undergo collection of tissue and blood samples

DRUG

MEK 162 therapy or molecularly targeted therapy

molecularly targeted therapy, MEK 162 therapy

PROCEDURE

therapeutic procedure

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

quality-of-life assessment

Ancillary studies

Trial Locations (8)

32224

Mayo Clinic Cancer Center, Jacksonville

37240

Vanderbilt University Medical Center, Nashville

48201

Barbara Ann Karmanos Cancer Institute, Detroit

55905

Mayo Clinic Cancer Center, Rochester

75246

Baylor Sammons Cancer Center, Dallas

85259-5499

Mayo Clinic Cancer Center, Scottsdale

06520-8028

Smilow Cancer Hospital at Yale-New Haven, New Haven

48109-0944

University of Michigan Comprehensive Cancer Center, Ann Arbor

All Listed Sponsors

lead

Yale University

OTHER

collaborator

National Cancer Institute (NCI)

NIH